[1]Xu LP, Wu DP, Han MZ, et al.A review of hematopoietic cell transplantation in China: data and trends during 2008-2016[J].Bone Marrow Transplant, 2017, 52(11):1512-1518
[2]Hingorani S.Renal Complications of Hematopoietic-Cell Transplantation[J].N Engl J Med, 2016, 374(23):2256-2267
[3]Liu Y, Xu L, Zhang X, et al.Acute kidney injury following haplo stem cell transplantation: incidence,risk factors and outcome[J].Bone Marrow Transplant, 2018, 53(4):483-486
[4]Parikh CR, Schrier RW, Storer B, et al.Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation[J].Am J Kidney Dis, 2005, 45(3):502-509
[5]Lopes JA, Jorge S, Neves M.Acute kidney injury in HCT: an update[J].Bone Marrow Transplant, 2016, 51(6):755-762
[6]Krishnappa V, Gupta M, Manu G, et al.Acute Kidney Injury in Hematopoietic Stem Cell Transplantation: A Review[J]. [J].Int J Nephrol, 2016, :5163789-
[7]Qin CJ, Liu LJ, Zhang ZM, et al.A clinical analysis of hepatic veno-occlusive disease after hematopoietic stem cell transplantation][J].Zhonghua Nei Ke Za Zhi, 2018, 57(7):483-486
[8]Sawinski D.The kidney effects of hematopoietic stem cell transplantation[J].Adv Chronic Kidney Dis, 2014, 21(1):96-105
[9]Moiseev IS, Babenko EV, Sipol AA, et al.Measurement of circulating endothelial cells to support the diagnosis of veno-occlusive disease after hematopoietic stem cell transplantation[J].Int J Lab Hematol, 2014, 36(4):e27-29
[10]Richardson PG, Riches ML, Kernan NA, et al.Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure[J].Blood, 2016, 127(13):1656-1665
[11]Cesaro S, Dalianis T, Hanssen Rinaldo C, et al.ECIL guidelines for the prevention,diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients[J].J Antimicrob Chemother, 2018, 73(1):12-21
[12]Yang N, Gao CJ.Research Advances on BK Virus Associated Hemorrhagic Cystitis after HSCT-Review][J].Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2018, 26(5):1565-1568
[13]Bruno B, Zager RA, Boeckh MJ, et al.Adenovirus nephritis in hematopoietic stem-cell transplantation[J].Transplantation, 2004, 77(7):1049-1057
[14]Sakurada M, Kondo T, Umeda M, et al.Successful treatment with intravesical cidofovir for virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: A case report and a review of the literature[J].J Infect Chemother, 2016, 22(7):495-500
[15]Zager RA, O'Quigley J, Zager BK, et al.Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients[J].Am J Kidney Dis, 1989, 13(3):210-216
[16]Parikh CR, McSweeney P, Schrier RW.Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant[J].Kidney Int, 2005, 67(5):1999-2005
[17]Abboud I, Porcher R, Robin M, et al.Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation[J].Biol Blood Marrow Transplant, 2009, 15(10):1251-1257
[18]Shimoi T, Ando M, Munakata W, et al.The significant impact of acute kidney injury on CKD in patients who survived over 10 years after myeloablative allogeneic SCT[J].Bone Marrow Transplant, 2013, 48(1):80-84
[19]Sakellari I, Barbouti A, Bamichas G, et al.GVHD-associated chronic kidney disease after allogeneic haematopoietic cell transplantation[J].Bone Marrow Transplant, 2013, 48(10):1329-1334
[20]Cohen EP, Drobyski WR, Moulder JE.Significant increase in end-stage renal disease after hematopoietic stem cell transplantation[J].Bone Marrow Transplant, 2007, 39(9):571-572
[21]Ando M.An Overview of Kidney Disease Following Hematopoietic Cell Transplantation[J].Intern Med, 2018, 57(11):1503-1508
[22]陈育红, 黄晓军, 郭乃榄, et al.异基因造血干细胞移植后急性移植物抗宿主病的发生及其危险因素的探讨[J].中华血液学杂志, 2003, 24(2):8-10
[23]陈瑶, 陆道培, 刘开彦, et al.异基因造血干细胞移植后急性移植物抗宿主病151例危险因素分析[J].中华血液学杂志, 2005, 26(02):13-16
[24]Sadeghi B, Al-Chaqmaqchi H, Al-Hashmi S, et al.Early-phase GVHD gene expression profile in target versus non-target tissues: kidney,a possible target?[J].Bone Marrow Transplant, 2013, 48(2):284-293
[25]Higo S, Shimizu A, Masuda Y, et al.Acute graft-versus-host disease of the kidney in allogeneic rat bone marrow transplantation[J].PLoS One, 2014, 9(12):e115399-
[26]Dhakal B, Singavi A, Cohen EP, et al.Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipientsIncidence,pattern and therapeutic outcomes[J].Bone Marrow Transplant, 2015, 50(3):449-451
[27]陈瑶, 黄晓军, 张晓辉.异基因造血干细胞移植后并发肾病综合征的单中心临床分析[J].中华内科杂志, 2011, 50(7):572-575
[28]Beyar-Katz O, Davila EK, Zuckerman T, et al.Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to Therapy[J].Biol Blood Marrow Transplant, 2016, 22(6):975-981
[29]Gavriilaki E, Sakellari I, Batsis I, et al.Transplant-associated thrombotic microangiopathy: Incidence,prognostic factors,morbidity,and mortality in allogeneic hematopoietic cell transplantation[J].Clin Transplant, 2018, 32(9):e13371-
[30]Elsallabi O, Bhatt VR, Dhakal P, et al.Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy[J].Clin Appl Thromb Hemost, 2016, 22(1):12-20
[31]Rosenthal J.Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment[J].J Blood Med, 2016, (7):181-186
[32]Jodele S, Zhang K, Zou F, et al.The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy[J].Blood, 2016, 127(8):989-996
[33]Obut F, Kasinath V, Abdi R.Post-bone marrow transplant thrombotic microangiopathy[J].Bone Marrow Transplant, 2016, 51(7):891-897
[34]Zhang XH, Liu X, Wang QM, et al.Thrombotic microangiopathy with concomitant GI aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome[J].Eur J Haematol, 2018, 100(2):171-181
[35]Jodele S, Davies SM, Lane A, et al.Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults[J].Blood, 2014, 124(4):645-653
[36]赵新菊, 连立超, 韦洮.血浆置换治疗不同病因血栓性微血管病的效果观察[J].中国血液净化, 2014, 13(02):85-89
[37]Kim SS, Patel M, Yum K, et al.Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options[J].Transfusion, 2015, 55(2):452-458
[38]Jodele S, Fukuda T, Mizuno K, et al.Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation[J].Biol Blood Marrow Transplant, 2016, 22(2):307-315
